Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy

International Journal of Biological Markers

Volumn 24, Issue 4, 2009, Pages 230-237

  Li, Xiao Qin ^a   Li, Jian ^a   Shi, Shun Bing ^a   Chen, Ping ^a   Yu, Li Chao ^a   Bao, Qian Lei ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; BCRP; ERCC1; LRP; MRP1; Non small cell lung cancer

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 76649129015     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.5437     Document Type: Article

References (27)

1. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.
2. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97.
3. Gurubhagavatula S, Lynch TJ. The role of adjuvant chemotherapy for non-small cell lung cancer. Semin Respir Crit Care Med 2005; 26: 298-303.
4. Hall M D, Okabe M, Shen D-W, Liang X-J, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008; 48: 495-535.
5. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006; 355: 1054-5.
6. Safaei R, Holzer A K, Katano K, Samimi G, Howell SB. The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 2004; 98: 1607-13.
7. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SPC, Deeley RG, Gerlach JH. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 1999; 5: 673-80.
8. Young LC, Campling BG, Cole SPC, Deeley RG, Gerlach JH. Multidrug resistance protein MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001; 7: 1798-804.
9. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-63.
10. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRPrelated and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004; 5: 21-53.
11. Laurençot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 1997; 72: 1021-6.
12. Scheffer GL, Schroeijers AB, Izquierdo WA, Wiemer EA, Scheper RJ. Lung resistance-related protein/major vault protein and vaults in multidrug-resistance cancer. Curr Opin Oncol 2000; 12: 550-6.
13. Dalton WS, Scheper RL. Lung resistance-related protein determining its role in multidrug resistance. J Natl Cancer Inst 1999; 91: 1604-5.
14. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC1 expression and repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000; 20: 645-52.
15. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistance ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000; 60: 1305-13.
16. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-91.
17. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-25.
18. Mountain CF. Revision in the international system for staging lung cancer. Chest 1997; 111: 1170-7.
19. Danesi R, de Braud F, Fogli S, et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003; 55: 57-103.
20. Berger W, Setinek U, Hollaus P, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005; 131: 355-63.
21. Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004;10: 1691-7
22. Filipits M, Haddad V, Schmid K, et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 2007; 13: 392-8
23. Bessho Y, Oguri T, Achiwa H, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 2006; 97: 192-8.
24. Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009; 64: 98-104.
25. Harada T, Ogura S, Yamazaki K, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003; 94: 394-9.
26. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-90.
27. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007; 98: 1336-43.